MedTrace Logo

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

NCT04183166 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

TG4050

Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks

Sponsors & Collaborators

  • Transgene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-12
Primary Completion
2027-12-30
Completion
2031-12-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04183166 on ClinicalTrials.gov